Yersinia pestis, the causative agent of plague is a bacteria that has caused zoonotic disease throughout recorded human history. This disease has been associated with untold human suffering and has affected the politics, trade and determined the fate of empires. Only over the last one hundred years have we been able to understand and implement countermeasures to control the spread of disease and reduce individual suffering. Processes to reduce exposure of humans to the insect vector and infected animals as well as use of quarantine procedures helped to reduce incidence of disease. The use of vaccines for plague began in the 1930s with limited and variable efficacy. However, beginning in the early 1990s a more deliberate vaccine design process was undertaken to create a medical countermeasure to protect against both natural and weaponized plague infection. This vaccine product known as rF1V will be described from its inception through approval as an orphan drug product in early 2017. Key data on vaccine design, testing, development, safety and efficacy will be discussed.
Tuesday, November 14, 2017 at 12:00pm to 1:00pm
Bond Life Sciences Center, 572
Columbia, MO 65211